UpdatedMar 26

Supreme Court Seems Skeptical of Challenge to Abortion Pill Access

Justices appeared skeptical that the doctors’ group challenging the FDA’s loosening of restrictions of mifepristone had standing to bring the case.

By Epoch Times Staff

| Published Mar 26, 2024 | Updated Mar 26, 2024

Save

Supreme Court Seems Skeptical of Challenge to Abortion Pill Access — U.S. Supreme Court in Washington on March 22, 2024. Madalina Vasiliu/The Epoch Times

Pinned

What to Know About Today's Hearing

By Catherine Yang

Mar 26

What to Know About Today's Hearing

By Catherine Yang

Mar 26

Case Concludes

Mar 26

Solicitor General Asks Court to Reverse 5th Circuit’s Ruling

By Samantha Flom

Mar 26

Barrett Asks About First Visits

By Catherine Yang

Mar 26

U.S. Supreme Court in Washington on March 22, 2024. (Madalina Vasiliu/The Epoch Times) — U.S. Supreme Court in Washington on March 22, 2024. Madalina Vasiliu/The Epoch Times

Justices’ Questions on Conscience Harm

By Savannah Hulsey Pointer

Mar 26

Sotomayor Challenges Doctors’ Conscience Objections

By Samantha Flom

Mar 26

Gorsuch Interrupts, Says Case 'Prime Example' of New Trend Supreme Court Has 'Never Adopted'

By Catherine Yang

Mar 26

Respondent Argues FDA Didn't Consider Safety Concerns

By Savannah Hulsey Pointer

Mar 26

Pharma lawyer: Judges ‘Not in a Position’ to Second-Guess FDA

By Samantha Flom

Mar 26

Alito Presses Drug Company on Stake in Case

By Catherine Yang

Mar 26

Justice Jackson Questions Possible ‘Mismatch’ In Injury Claim

By Savannah Hulsey Pointer

Mar 26

FDA Argues Conscience Protections Apply

By Catherine Yang

Mar 26

Alito Raises Concern About Studies Showing Increased Emergency Room Visits

By Samantha Flom

Mar 26

FDA: Not Responsible for Considering Law Against Mailing 'Obscene' Material

By Catherine Yang

Mar 26

Roberts Asks if Higher ER Visits Would Change Argument

By Catherine Yang

Mar 26

Government Asserts No Standing to Challenge FDA

By Savannah Hulsey Pointer

Mar 26

Justice Thomas: Who Has Standing to Challenge?

By Samantha Flom

Mar 26

FDA Gives Opening Statement

By Catherine Yang

Mar 26

Sen. Josh Hawley's Wife Represents Challengers

By Savannah Hulsey Pointer

Mar 26

Students for Life Presses Pharmacies to Stop Distributing Abortion Pills

By Samantha Flom

Mar 26

March for Life: FDA Failed to Meet Its Own Standards

By Samantha Flom

Mar 26

Catholic Organization Chides FDA for ‘Endangering and Abandoning’ Women

Mar 26

Pro-life protesters outside the Supreme Court before the major challenge to abortion pill access on March 26, 2024. (Sam Dorman/The Epoch Times) — Pro-life protesters outside the Supreme Court before the major challenge to abortion pill access on March 26, 2024. Sam Dorman/The Epoch Times

Dueling Protests

By Sam Dorman

Mar 26

Pro-life protesters stage a "die-in" outside the Supreme Court ahead of a major challenge to abortion pill access on March 26, 2024. (Sam Dorman/The Epoch Times) — Pro-life protesters stage a "die-in" outside the Supreme Court ahead of a major challenge to abortion pill access on March 26, 2024. Sam Dorman/The Epoch Times

Pro-abortion protesters outside the Supreme Court ahead of a challenge to abortion pill access on March 26, 2024. (Sam Dorman/The Epoch Times) — Pro-abortion protesters outside the Supreme Court ahead of a challenge to abortion pill access on March 26, 2024. Sam Dorman/The Epoch Times

What to Know

By Sam Dorman and Matthew Vadum

Mar 26

Supreme Court Will Soon Be Hearing on Abortion Drug Access

By Naveen Athrappully

Mar 23

Supreme Court Will Soon Be Hearing on Abortion Drug Access — Pro-abortion activists (R) argue with pro-life activists in front of the Supreme Court in Washington on June 26, 2022. Nathan Howard/Getty Images

The U.S. Supreme Court will start hearing arguments against the abortion drug mifepristone beginning this week, with a decision expected in three months.

The abortion pill challenge concerns mifepristone, one of the two drugs used for medical abortions in the United States. Two cases have been filed—one against Danco Laboratories, which manufactures mifepristone, and the second against the Food and Drug Administration (FDA). The cases are consolidated into one, with the U.S. Supreme Court set to hear oral arguments in the case on March 26. A decision on the matter is expected roughly three months later.

Abortion supporters argue that mifepristone has been proven safe and that blocking the drug would harm the interests of millions of women. However, opponents claim that the FDA made two changes related to mifepristone in 2016 and 2021 that removed key safety protocols protecting women.

Studies Cited in Major Abortion Pill Ruling Retracted Due to Politics, Researchers Say

By Samantha Flom

Mar 18

Studies Cited in Major Abortion Pill Ruling Retracted Due to Politics, Researchers Say — Charlotte Lozier Institute Senior Research Associate Tessa Longbons Cox is photographed on April 12, 2018. Anastasia Rowan/Susan B. Anthony Pro-Life America

The Charlotte Lozier Institute (CLI) makes no effort to hide its ties to the pro-life cause.

As the 501(c)(3) research and education arm of Susan B. Anthony Pro-Life America, the institute is forthright about where it stands on abortion and other reproductive issues.

Since its founding in 2011, the organization’s network of scholars in medicine, public health, science, and other disciplines has published dozens of peer-reviewed studies on those topics. And until recently, that hadn’t posed a problem.

Supreme Court to Rule on Biggest Abortion Case Since Overturning of Roe v. Wade

By Matthew Vadum

Jan 15

Supreme Court to Rule on Biggest Abortion Case Since Overturning of Roe v. Wade — Illustration by The Epoch Times, Shutterstock

Legal experts are divided over how the Supreme Court will rule in an upcoming challenge to federal regulations that relaxed restrictions in 2016 and 2021 on the commonly used abortion pill mifepristone.

Advocates for mifepristone say the current system by which the drug is provided is safe, while opponents say it puts women at risk by ignoring the safety measures that used to be in place.

The Biden administration and pro-abortion groups worry that the Supreme Court’s eventual decision in the case could affect the availability of the drug.